Yes and they lined out their priorities during the December CC (I believe was when NP stated them). I don't recall if BLA or cancer was 1 or 2, but they were and are the main priorities for funding. NASH, mono pivotal trial, MS, GvHD, etc. will not focused on until funding allows, but I would guess license deals are and will be worked as time allows as Dr. Rae is on salary and thus only a little additional costs associated.....and preclinical trials to submit IND for P2 for those indications not already approved for P2. Basically all the cheap things associated with adding value to the company but not advancing the associated trials.

Their actions support these priorities, however funding still seems to impact even the top 2. China cancer and/or NASH appear to be the priority license deals.....followed by EU HIV. Success with debt financing and warrants being exercised as CE noted yesterday will help significantly bridge the gap until a license deal can get completed.